InMode Ltd. (INMD)
InMode: Product Origination And Undervaluation Make The Stock A Buy
InMode Ltd. demonstrates impressive net income growth from non-invasive surgical products, with new platforms Define and Envision expected to drive future business growth. The company's innovative technologies in plastic surgery, dermatology, gynecology, and ophthalmology, along with ongoing stock repurchases, make InMode a compelling buy. Strong financials show consistent income growth and significant cash flow, with minimal liabilities, indicating a robust financial position and undervaluation.
InMode: $25/Share Is Closer Than You Think
Elevated interest rates continue to hurt InMode's revenue, especially as lease package interest rates haven't fallen yet. Still, future rate cuts could release pent-up demand. InMode continues to buy back shares at a low price, which will boost per-share results. InMode's manufacturing is done in Israel, presenting a risk, but the company has been managing this well despite the war.
InMode: A Deep Dive After Q3 Earnings
InMode's products are part of the medical aesthetics industry that is expected to grow at an 11% CAGR over the next five years. Despite a punishing macro environment of late that has seen its share price decline over 80% from its peak, InMode has remained profitable while continuing to innovate. The strong new and second-hand sales market for their platforms suggest their customers continue to see value in their products.
InMode Ltd. (INMD) Q3 2024 Earnings Call Transcript
InMode Ltd. (NASDAQ:INMD ) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET Company Participants Miri Segal - CEO, MS-IR Moshe Mizrahy - Chief Executive Officer Michael Kreindel - Chief Technology Officer Yair Malca - Chief Financial Officer Eran Krieger - Medical Director and VP of Medical Affairs Rafael Lickerman - Vice President, Finance Conference Call Participants Matt Miksic - Barclays Caitlin Cronin - Canaccord Genuity Sam Eiber - BTIG Operator Good day, and welcome to the InMode's Third Quarter 2024 Earnings Results Conference Call.
InMode (INMD) Q3 Earnings and Revenues Beat Estimates
InMode (INMD) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.61 per share a year ago.
Pomerantz Law Firm Announces Filing Deadline in Class Action Against InMode Ltd. and Certain Officers – INMD
NEW YORK, NY / ACCESSWIRE / October 28, 2024 / Pomerantz LLP hereby advises investors of recent developments in the class action lawsuit Cement Masons' and Plasterers' Local No. 502 Pension Fund v.
Earnings Preview: InMode (INMD) Q3 Earnings Expected to Decline
InMode (INMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is InMode (INMD) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy InMode (INMD) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
InMode Offers High Risk-Reward Opportunity Amid New Products And Rate Cuts (Rating Upgrade)
InMode's Q2 2024 revenue dropped by 36.5% year-over-year to $86.4 million, underlining macroeconomic challenges. The company revised its full-year 2024 revenue guidance to $430-$440 million due to slower platform rollouts and production delays. Lower interest rates from Federal Reserve cuts could boost demand for InMode's minimally invasive treatments, benefiting from reduced financing costs.
Are Investors Undervaluing InMode (INMD) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
InMode Stock: An Inverse Bubble Caused By Short-Term Trouble
InMode stock has significant upside potential due to its low valuation, profitability, share buybacks, and potential benefits from expected interest rate cuts. INMD's business model involves selling high-quality, expensive medical devices for aesthetic procedures, heavily influenced by interest rates due to customer financing. The stock's decline was driven by underutilized buybacks, declining revenue, and high interest rates, but recent buybacks and potential rate cuts offer a brighter outlook.
